K251873 is an FDA 510(k) clearance for the Saige-Dx. This device is classified as a Radiological Computer Assisted Detection/diagnosis Software For Lesions Suspicious For Cancer (Class II — Special Controls, product code QDQ).
Submitted by DeepHealth, Inc. (Somerville, US). The FDA issued a Cleared decision on August 11, 2025, 54 days after receiving the submission on June 18, 2025.
This device falls under the Radiology FDA review panel. Regulated under 21 CFR 892.2090. A Radiological Computer Assisted Detection And Diagnostic Software For Suspected Lesions Is An Image Processing Device Intended To Aid In The Detection, Localization, And Characterization Of Lesions Suspicious For Cancer On Acquired Medical Images (e.g., Mammography , Mr, Ct, Ultrasound, Radiography). The Device Detects, Identifies And Characterizes Lesions Suspicious For Cancer Based On Features Or Information Extracted From The Images, And May Provide Information About The Presence, Location, And Characteristics Of The Lesion To The User. Primary Diagnostic And Patient Management Decisions Are Made By The Clinical User..